Kiadis appoints Vincent Brichard to board
This article was originally published in Scrip
Executive Summary
Kiadis, a clinical-stage biopharmaceutical company developing immunotherapy treatments, has appointed Dr Vincent Brichard an independent member of its supervisory board. Dr Brichard, a physician by training, has more than 25 years' experience in the oncology and immunology field, including almost 15 years at GlaxoSmithKline where he was senior vice-president and had responsibility for the Immunotherapeutics Business Unit. In addition to this position, he served as a member of the board of directors at GSK Biologicals.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.